Clinical Trial Update: The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study [Phase 2]

View source ↗

Summary

A Phase II multicenter trial is evaluating glofitamab in combination with a PD-1 antibody and lenalidomide for relapsed/refractory Large B-cell Lymphoma with TP…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• Lenalidomide (lenalidomide)
• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Large B-cell Lymphoma, TP53 | Phase 2 | Status: RECRUITING